Furthermore, the ability of roneparstat to inhibit multiple myeloma growth and angiogenesis has been correlated with disruption of the heparanase/syndecan-1 axis and downregulation of HGF, VEGF and MMP-9 gene expression controlled by endogenous heparanase in myeloma cells [44, 45]. Here, HGF is linked to plasma cell myeloma.